Skip to the beginning of the images gallery

Lenalidomide - ≥99%, high purity , CRL4(CRBN) E3 ubiquitin ligase inhibitor, CAS No.191732-72-6, CRL4(CRBN) E3 ubiquitin ligase inhibitor

2 Citations

Moligand™

≥99%

CAS#: 191732-72-6
Formula: C₁₃H₁₃N₃O₃
Molecular Weight: 259.27
EC Number: 691-297-1
PubChem CID: 216326

Item Number

L125046

Grouped product items
SKU	Size	Availability	Price
L125046-50mg	50mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$14.90
L125046-250mg	250mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$58.90
L125046-1g	1g	In stock	$195.90
L125046-5g	5g	In stock	$882.90
L125046-10g	10g	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,587.90
L125046-25g	25g	In stock	$3,572.90
L125046-100g	100g	In stock	$12,859.90

Thalidomide analog, TNF-α inhibitor

View related series

Apoptosis cereblon Ligands for E3 Ligase Molecular Glues PROTAC

Basic Description

Synonyms	CC-5013 \| (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione \| 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)- \| ENMD 0997 \| Q425681 \| LENALIDOMIDE [VANDF] \| AB01273975-01 \| 1-benzylpiperidin-4-one oxime;1-Benzyl-4-piperidinone Oxi
Specifications & Purity	Moligand™, ≥99%
Biochemical and Physiological Mechanisms	Lenalidomide is a thalidomide analog known to inhibit TNF-α secretion and possess immunomodulatory properties.Thalidomide analog and TNF-α inhibitor. Potent antitumor and anti-inflammatory effects. Modulates and potentiates host immune responses against m
Storage Temp	Store at -20°C,Argon charged
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	CRL4(CRBN) E3 ubiquitin ligase inhibitor
Note	Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description	Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM. A Thalidomide analog known to have immunomodulatory properties

Product Properties

ALogP	-0.5

Associated Targets(Human)

CRBN Tclin Protein cereblon (0 Activities)

Discover Target: CRBN

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

F2 Tclin Thrombin (11687 Activities)

Discover Target: F2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ESR1 Tclin Estrogen receptor alpha (17718 Activities)

Discover Target: ESR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PGR Tclin Progesterone receptor (8562 Activities)

Discover Target: PGR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)

Discover Target: CHRM2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)

Discover Target: HTR1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)

Discover Target: ADRA2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AR Tclin Androgen Receptor (11781 Activities)

Discover Target: AR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)

Discover Target: CHRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)

Discover Target: GABRA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAOA Tclin Monoamine oxidase A (11911 Activities)

Discover Target: MAOA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD1 Tclin Dopamine D1 receptor (9720 Activities)

Discover Target: DRD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ACHE Tclin Acetylcholinesterase (18204 Activities)

Discover Target: ACHE

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)

Discover Target: PTGS1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A2 Tclin Norepinephrine transporter (10102 Activities)

Discover Target: SLC6A2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A4 Tclin Serotonin transporter (12625 Activities)

Discover Target: SLC6A4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)

Discover Target: ADRA1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRM1 Tclin Mu opioid receptor (19785 Activities)

Discover Target: OPRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD3 Tclin Dopamine D3 receptor (14368 Activities)

Discover Target: DRD3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A3 Tclin Dopamine transporter (10535 Activities)

Discover Target: SLC6A3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KCNH2 Tclin HERG (29587 Activities)

Discover Target: KCNH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDE3A Tclin Phosphodiesterase 3A (3309 Activities)

Discover Target: PDE3A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 Activities)

Discover Target: HTR2B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TBXA2R Tclin Thromboxane A2 receptor (5717 Activities)

Discover Target: TBXA2R

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDE4A Tclin Phosphodiesterase 4A (1943 Activities)

Discover Target: PDE4A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA3 Tchem Adenosine A3 receptor (15931 Activities)

Discover Target: ADORA3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH3 Tclin Histamine H3 receptor (10389 Activities)

Discover Target: HRH3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)

Discover Target: KDR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

STAT3 Tchem Signal transducer and activator of transcription 3 (3313 Activities)

Discover Target: STAT3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Homo sapiens (32628 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

5637 (630 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A 172 (535 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A204 (242 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A2058 (690 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A-375 (9258 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A-427 (643 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A498 (42825 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A673 (619 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ACHN (49357 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AGS (1999 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

BT-20 (503 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

BT-474 (2113 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

BXPC-3 (2997 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

C8166 (1658 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CAKI-1 (44928 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Calu-3 (339 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Calu-6 (398 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CAPAN-1 (772 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CCRF-CEM (65223 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CFPAC-1 (421 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

COR-L23 (253 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RAW264.7 (28094 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

H4 (48 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rep Replicase polyprotein 1ab (378 Activities)

Discover Target: rep

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Rela Transcription factor p65 (175 Activities)

Discover Target: Rela

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Cereblon isoform 4 (52 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SARS-CoV-2 (38078 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Names and Identifiers

IUPAC Name	3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
INCHI	InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChi Key	GOTYRUGSSMKFNF-UHFFFAOYSA-N
Canonical SMILES	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
Isomeric SMILES	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
Alternate CAS	191732-72-6
PubChem CID	216326
NSC Number	747972
MeSH Entry Terms	2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-;3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione;CC 5013;CC-5013;CC5013;IMiD3 cpd;lenalidomide;Revimid;Revlimid
Molecular Weight	259.27

Database links

DrugBank Ligand	DB00480
PubChem CID	216326
CAS Registry No.	191732-72-6
ChEMBL Ligand	CHEMBL848
Wikipedia	Lenalidomide
Reactome Reaction	R-HSA-9681169
Reactome Drug	R-ALL-9681174
DrugCentral Ligand	3317

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

10 results found

Lot Number	Certificate Type	Date	Item
K2124035	Certificate of Analysis	Sep 19, 2023	L125046
K2124144	Certificate of Analysis	Sep 19, 2023	L125046
K2124146	Certificate of Analysis	Sep 19, 2023	L125046
J1515152	Certificate of Analysis	May 10, 2023	L125046
B2307271	Certificate of Analysis	Feb 14, 2023	L125046
D2017093	Certificate of Analysis	Feb 23, 2022	L125046
C2205155	Certificate of Analysis	Sep 16, 2021	L125046
C23241061	Certificate of Analysis	Sep 16, 2021	L125046
E2408054	Certificate of Analysis	Sep 16, 2021	L125046
F23061525	Certificate of Analysis	Sep 16, 2021	L125046

Chemical and Physical Properties

Solubility	Soluble in DMSO (≥52 mg/ml) at 25 °C, methanol and water (2: 1), buffered aqueous solvents, water (<1 mg/ml) at 25 °C, and ethanol (<1 mg/ml) at 25 °C.
Sensitivity	Heat sensitive

Safety and Hazards(GHS)

Pictogram(s)	GHS06, GHS08, GHS07
Signal	Danger
Hazard Statements	H301:Toxic if swallowed H302:Harmful if swallowed H312:Harmful in contact with skin H332:Harmful if inhaled H372:Causes damage to organs through prolonged or repeated exposure H360:May damage fertility or the unborn child
Precautionary Statements	P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P271:Use only outdoors or in a well-ventilated area. P270:Do not eat, drink or smoke when using this product. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P203:Obtain, read and follow all safety instructions before use. P301+P316:IF SWALLOWED: Get emergency medical help immediately. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P317:Get emergency medical help. P319:Get medical help if you feel unwell.

FAQs and Articles

FAQ

Targeted protein degradation technology: proprietary drugs are not difficult, drug resistance is no longer

Categories: Technical articles

Tags:

Small Molecule Drugs Targeted protein degradation PROTAC HTS Tumors

Citations of This Product

How to Cite Aladdin Scientific Products?

1. Xiaohe Li, Qing Liang, Shaoyan Gao, Qiuyan Jiang, Fangxia Zhang, Ruiqin Zhang, Hao Ruan, Shuangling Li, Jiaoyan Luan, Ruxia Deng, Honggang Zhou, Hui Huang, Cheng Yang. (2022) Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway. INTERNATIONAL IMMUNOPHARMACOLOGY, 103 (108470). [PMID:34952465] [10.1016/j.intimp.2021.108470]
2. Yue-Yue Chang, Hai-Long Wu, Huan Fang, Tong Wang, Yang-Zi Ouyang, Xiao-Dong Sun, Gao-Yan Tong, Yu-Jie Ding, Ru-Qin Yu. (2021) Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples. TALANTA, 224 (121798). [PMID:33379025] [10.1016/j.talanta.2020.121798]

References

1. Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ. (2009) Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.. PLoS ONE, 4 (2): (e4583). [PMID:19240791] [10.1021/op500134e]
2. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL et al.. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.. Blood, 118 (18): (4771-9). [PMID:21860026] [10.1021/op500134e]
3. Petzold G, Fischer ES, Thomä NH. (2016) Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.. Nature, 532 (7597): (127-30). [PMID:26909574] [10.1021/op500134e]
4. Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK et al.. (2015) Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.. Nature, 523 (7559): (183-188). [PMID:26131937] [10.1021/op500134e]
5. Xiaohe Li, Qing Liang, Shaoyan Gao, Qiuyan Jiang, Fangxia Zhang, Ruiqin Zhang, Hao Ruan, Shuangling Li, Jiaoyan Luan, Ruxia Deng, Honggang Zhou, Hui Huang, Cheng Yang. (2022) Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway. INTERNATIONAL IMMUNOPHARMACOLOGY, 103 (108470). [PMID:34952465] [10.1016/j.intimp.2021.108470]
6. Yue-Yue Chang, Hai-Long Wu, Huan Fang, Tong Wang, Yang-Zi Ouyang, Xiao-Dong Sun, Gao-Yan Tong, Yu-Jie Ding, Ru-Qin Yu. (2021) Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples. TALANTA, 224 (121798). [PMID:33379025] [10.1016/j.talanta.2020.121798]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Lenalidomide - ≥99%, high purity , CRL4(CRBN) E3 ubiquitin ligase inhibitor, CAS No.191732-72-6, CRL4(CRBN) E3 ubiquitin ligase inhibitor

Basic Description

Product Properties

Associated Targets(Human)

Associated Targets(non-human)

Mechanisms of Action

Names and Identifiers

Database links

Certificates

Certificate of Analysis(COA)

Chemical and Physical Properties

Safety and Hazards(GHS)

Related Documents

FAQs and Articles

Citations of This Product

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator